Scientists test novel drug duo in fight against Tough-to-Treat cancers
NCT ID NCT07137416
Summary
This early-phase study aims to find a safe and tolerable dose of a new drug combination for people with advanced breast cancer and other solid tumors that have a protein called HER2. The trial will test pidnarulex, which aims to stop tumor cell growth, together with an existing targeted chemotherapy drug called trastuzumab deruxtecan. Researchers will enroll about 36 adults to see if the combination is safe and shows signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber - Harvard Cancer Center LAO
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.